N. Stanulovic, T. Ivković-Kapicl, A. Mandić, B. Gutic
Background: Tumor budding is recognized as an important independent prognostic factor in colorectal carcinoma. The aim of this study was to evaluate the grade of tumor budding and association with other clinical and pathological features in patients with cervical carcinoma. Material and methods: We evaluated pathohistological data from 91 cervical carcinoma patients (mean age: 53.8 years) who underwent radical hysterectomy and pelvic lymphatic dissection at the Oncology Institute of Vojvodina between January 2010 and December 2018. Tumor budding was evaluated in invasive front of the tumor. Based on the number of bud counts/10 high power field, three groups were formed: with no budding, with less than 15 buds, and with more than 15 buds. Results: Eighty (87.91%) of evaluated cervical carcinomas were squamous-cell type, while 12.09% were adenocarcinomas. All carcinomas were graded (HG1-HG3). Average diameter of the tumors was 25 mm (81.6% < 4 cm and 18.4% > 4 cm). Metastases in lymph nodes were present in 30 (32.9%) cases. Based on the number of bud counts/10 high power field there were 35.1% with no budding, 32.9% with less than 15 buds and 37.3% with more than 15 buds. There was a significant association between tumor budding grade and histological grade (p=0.04), as well as with tumor budding grade and the diameter of the tumor (p=0.04). Conclusion: As a quantitative measure of cancer cell dissociation, tumor budding is associated with poor prognosis in cervical carcinoma and should be considered as a prognostic factor.
{"title":"Tumor budding in cervical carcinoma: Associations with some clinical and pathological factors","authors":"N. Stanulovic, T. Ivković-Kapicl, A. Mandić, B. Gutic","doi":"10.2298/aoo200124003s","DOIUrl":"https://doi.org/10.2298/aoo200124003s","url":null,"abstract":"Background: Tumor budding is recognized as an important independent prognostic factor in colorectal carcinoma. The aim of this study was to evaluate the grade of tumor budding and association with other clinical and pathological features in patients with cervical carcinoma. Material and methods: We evaluated pathohistological data from 91 cervical carcinoma patients (mean age: 53.8 years) who underwent radical hysterectomy and pelvic lymphatic dissection at the Oncology Institute of Vojvodina between January 2010 and December 2018. Tumor budding was evaluated in invasive front of the tumor. Based on the number of bud counts/10 high power field, three groups were formed: with no budding, with less than 15 buds, and with more than 15 buds. Results: Eighty (87.91%) of evaluated cervical carcinomas were squamous-cell type, while 12.09% were adenocarcinomas. All carcinomas were graded (HG1-HG3). Average diameter of the tumors was 25 mm (81.6% < 4 cm and 18.4% > 4 cm). Metastases in lymph nodes were present in 30 (32.9%) cases. Based on the number of bud counts/10 high power field there were 35.1% with no budding, 32.9% with less than 15 buds and 37.3% with more than 15 buds. There was a significant association between tumor budding grade and histological grade (p=0.04), as well as with tumor budding grade and the diameter of the tumor (p=0.04). Conclusion: As a quantitative measure of cancer cell dissociation, tumor budding is associated with poor prognosis in cervical carcinoma and should be considered as a prognostic factor.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68403103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. Knežević, R. Srećković, A. Vulović, S. M. Jandric-Kocic
at the time of diagnosis. The patient underwent an extensive surgical resection of tumor with ex-tempore biopsy. Macroscopically, the mass measuring 5×5.5×4 cm was firm, relatively well-circumscribed, and lobulated with a gray-white cut surface. Pathohistological findings showed high-grade primary malignant mesenchymal tumor of the biphasic synovial sarcoma type, cystic subtype that was positive for CK AE1/AE3 focally, CK7 diffuse, CK19 focally, EMA focally-diffuse-1, Vimentin diffuse, Bcl-2 diffuse, CD99 diffuse, Ki-67 positive in > 70% of resection margin and TTF-1, CD34, and CK20 negative. The pathological findings were with viable cells on the margins, so the wide excision was followed by radiotherapy treatment with a total dose of 50 Gray in 25 fractions locally over five weeks. The tumor recurred locally within one year - a follow-up MRI scan after 9 months showed a dominant tumor of 7x7x6.5 cm and one smaller tumor in the distal femoral epiphysis. Tumors had smooth, well defined follow up after one year revealed tumor recurrence. Neurovascular bundle involvement was detected, but without adjacent bone and muscular invasion and above-the-knee partial amputation of the left leg was performed. The intervention resulted in a remission of the neoplastic process and the patient was scheduled for regular check-ups. Broad surgical resection of the tumor with negative margins was the primary treatment in this case. Mutilating operations are necessary when anatomical structures around the tumor do not allow complete reintervention.
{"title":"Synovial sarcoma of the popliteal fossa","authors":"B. Knežević, R. Srećković, A. Vulović, S. M. Jandric-Kocic","doi":"10.2298/AOO200915001K","DOIUrl":"https://doi.org/10.2298/AOO200915001K","url":null,"abstract":"at the time of diagnosis. The patient underwent an extensive surgical resection of tumor with ex-tempore biopsy. Macroscopically, the mass measuring 5×5.5×4 cm was firm, relatively well-circumscribed, and lobulated with a gray-white cut surface. Pathohistological findings showed high-grade primary malignant mesenchymal tumor of the biphasic synovial sarcoma type, cystic subtype that was positive for CK AE1/AE3 focally, CK7 diffuse, CK19 focally, EMA focally-diffuse-1, Vimentin diffuse, Bcl-2 diffuse, CD99 diffuse, Ki-67 positive in > 70% of resection margin and TTF-1, CD34, and CK20 negative. The pathological findings were with viable cells on the margins, so the wide excision was followed by radiotherapy treatment with a total dose of 50 Gray in 25 fractions locally over five weeks. The tumor recurred locally within one year - a follow-up MRI scan after 9 months showed a dominant tumor of 7x7x6.5 cm and one smaller tumor in the distal femoral epiphysis. Tumors had smooth, well defined follow up after one year revealed tumor recurrence. Neurovascular bundle involvement was detected, but without adjacent bone and muscular invasion and above-the-knee partial amputation of the left leg was performed. The intervention resulted in a remission of the neoplastic process and the patient was scheduled for regular check-ups. Broad surgical resection of the tumor with negative margins was the primary treatment in this case. Mutilating operations are necessary when anatomical structures around the tumor do not allow complete reintervention.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68403232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Haryani, Yati Afiyanti, B. Besral, D. Gayatri, Kemala Rita Wahidi, Hana Pramiasti, Ariesta Milanti
Background: The number of gynecological cancer survivors in Indonesia is growing, yet little is recognized about their supportive care needs due to a lack of validated assessment to measure them. This study aimed to culturally adapt the Cancer survivors? unmet needs into Indonesian language and to test its validity and reliability for Indonesian gynecological cancer patients. Methods: We performed the translation and adaptation of the Cancer survivors? unmet needs based on Beaton?s cross-cultural adaptation process of self-report measure. We then evaluated the psychometric properties of Cancer survivors? unmet needs -Indonesian with 298 participants from three hospitals across Indonesia. Results: Five factors were extracted from Exploratory Factor Analysis with factor loading >0.4. Cancer survivors? unmet needs - Indonesian had negative correlations with The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, indicating that the higher score of unmet needs resulted in the lower score of quality of life. The Cronbach?s ? coefficient for the Cancer survivors? unmet needs - Indonesian ranged from 0.75-0.95. Conclusions: The Cancer survivors? unmet needs - Indonesian version offers a valid and reliable scale for assessing supportive care needs among Indonesian gynecological cancer patients. The Cancer survivors? unmet needs-Indonesian could help clinicians to assess supportive care needs among Indonesian gynecological cancer patients. The low-resource countries such as Indonesia could use the evidence from the Cancer survivors? unmet needs assessment to develop the supportive care service in the clinical settings.
{"title":"Cross-cultural adaptation and validation of the cancer survivors’ unmet needs measure among gynecological cancer patients in Indonesia","authors":"H. Haryani, Yati Afiyanti, B. Besral, D. Gayatri, Kemala Rita Wahidi, Hana Pramiasti, Ariesta Milanti","doi":"10.2298/aoo190531011h","DOIUrl":"https://doi.org/10.2298/aoo190531011h","url":null,"abstract":"Background: The number of gynecological cancer survivors in Indonesia is growing, yet little is recognized about their supportive care needs due to a lack of validated assessment to measure them. This study aimed to culturally adapt the Cancer survivors? unmet needs into Indonesian language and to test its validity and reliability for Indonesian gynecological cancer patients. Methods: We performed the translation and adaptation of the Cancer survivors? unmet needs based on Beaton?s cross-cultural adaptation process of self-report measure. We then evaluated the psychometric properties of Cancer survivors? unmet needs -Indonesian with 298 participants from three hospitals across Indonesia. Results: Five factors were extracted from Exploratory Factor Analysis with factor loading >0.4. Cancer survivors? unmet needs - Indonesian had negative correlations with The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, indicating that the higher score of unmet needs resulted in the lower score of quality of life. The Cronbach?s ? coefficient for the Cancer survivors? unmet needs - Indonesian ranged from 0.75-0.95. Conclusions: The Cancer survivors? unmet needs - Indonesian version offers a valid and reliable scale for assessing supportive care needs among Indonesian gynecological cancer patients. The Cancer survivors? unmet needs-Indonesian could help clinicians to assess supportive care needs among Indonesian gynecological cancer patients. The low-resource countries such as Indonesia could use the evidence from the Cancer survivors? unmet needs assessment to develop the supportive care service in the clinical settings.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68402696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nikolina Dukić, Z. Gojković, Jelena Vladičić-Mašić, S. Mašić, Nenad Lalović, S. Popovic
Received 2018-11-12 Received in revised form 2019-05-22 Accepted 2019-05-29 INTRODUCTION Breast cancer is the most common malignant disease in women (1). It makes up about 26.5% of all newly discovered malignancies in the European female population and is responsible for 17.5% of the deaths. In males, this type of cancer is rare (one man per 100 women) (2). The frequency of the disease differs in various parts of the world. It is rarely seen before the age of 30, it rises with age and reaches its maximum around the age of 50 (3). The incidence of breast cancer in the world increases by 1-2% per year, and it is estimated that in the first decade of the third millennium, almost one million of women will suffer from breast cancer (4). However, in spite of the increasing possibilities of treatment, survival depends primarily on the extent and stage of the disease at the time of detection. In the early stage of the disease in which the largest number of patients is detected, healing is quite possible. Still, 24-30% of patients with lymph node negative and 50-60% with lymph node positive breast cancer will develop relapse. At the moment of diagnosis metastatic disease is present in 6-10% of patients (5). Treatment of breast cancer is multidisciplinary. Combination of surgical treatment, radiation and systemic therapeutic treatment ensure good results in patient survival. The type and order of particular treatments must be planned multidisciplinary by surgeons-oncologists, radiotherapists and internists-oncologists (6). Clinical features of tumor such as size, the existence of tumor cells in the armpit lymph nodes, and distant metastases are considered essential in determining prognosis and choices of treatment. Prognostic factors, derived from breast tissue after biopsy or surgery, have significance in measuring tumor aggressiveness and general disease prognosis. The standard prognostic parameters are patient (menopausal status, age) and tumor related (tumor size, histological type, axillary lymphatic status, tumor gradient, ER, PR and HER2 status). Some of them (ER, PR and HER2 status) have a predictive value because the best therapeutic modality is chosen based on these. According to St. Gallen Consensus and ESMO recommendations from year 2013 breast cancers fall into different types according to histopathological findings and results of predictive and prognostic tests. Based on this, specific therapeutic approach is recommended. When luminal A type patient receive only endocrine therapy, and chemotherapy is considered only in cases of high risk tumor (with four or more positive lymph nodes, tumor size T3 or tumor grade 3). When luminal B-like type (HER2 negative) patient is treated using chemotherapy and endocrine therapy. When luminal B-like (HER2 positive) patient is treated using chemotherapy, anti-HER2 and endocrine therapy. In case of non-luminal (HER2 positive) breast cancer type chemoand anti-HER2 therapy is recommended. In patients with basa
{"title":"Adjuvant application of trastuzumab in HER2 positive breast cancer and impact on time to relapse","authors":"Nikolina Dukić, Z. Gojković, Jelena Vladičić-Mašić, S. Mašić, Nenad Lalović, S. Popovic","doi":"10.2298/aoo181112006d","DOIUrl":"https://doi.org/10.2298/aoo181112006d","url":null,"abstract":"Received 2018-11-12 Received in revised form 2019-05-22 Accepted 2019-05-29 INTRODUCTION Breast cancer is the most common malignant disease in women (1). It makes up about 26.5% of all newly discovered malignancies in the European female population and is responsible for 17.5% of the deaths. In males, this type of cancer is rare (one man per 100 women) (2). The frequency of the disease differs in various parts of the world. It is rarely seen before the age of 30, it rises with age and reaches its maximum around the age of 50 (3). The incidence of breast cancer in the world increases by 1-2% per year, and it is estimated that in the first decade of the third millennium, almost one million of women will suffer from breast cancer (4). However, in spite of the increasing possibilities of treatment, survival depends primarily on the extent and stage of the disease at the time of detection. In the early stage of the disease in which the largest number of patients is detected, healing is quite possible. Still, 24-30% of patients with lymph node negative and 50-60% with lymph node positive breast cancer will develop relapse. At the moment of diagnosis metastatic disease is present in 6-10% of patients (5). Treatment of breast cancer is multidisciplinary. Combination of surgical treatment, radiation and systemic therapeutic treatment ensure good results in patient survival. The type and order of particular treatments must be planned multidisciplinary by surgeons-oncologists, radiotherapists and internists-oncologists (6). Clinical features of tumor such as size, the existence of tumor cells in the armpit lymph nodes, and distant metastases are considered essential in determining prognosis and choices of treatment. Prognostic factors, derived from breast tissue after biopsy or surgery, have significance in measuring tumor aggressiveness and general disease prognosis. The standard prognostic parameters are patient (menopausal status, age) and tumor related (tumor size, histological type, axillary lymphatic status, tumor gradient, ER, PR and HER2 status). Some of them (ER, PR and HER2 status) have a predictive value because the best therapeutic modality is chosen based on these. According to St. Gallen Consensus and ESMO recommendations from year 2013 breast cancers fall into different types according to histopathological findings and results of predictive and prognostic tests. Based on this, specific therapeutic approach is recommended. When luminal A type patient receive only endocrine therapy, and chemotherapy is considered only in cases of high risk tumor (with four or more positive lymph nodes, tumor size T3 or tumor grade 3). When luminal B-like type (HER2 negative) patient is treated using chemotherapy and endocrine therapy. When luminal B-like (HER2 positive) patient is treated using chemotherapy, anti-HER2 and endocrine therapy. In case of non-luminal (HER2 positive) breast cancer type chemoand anti-HER2 therapy is recommended. In patients with basa","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68403003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jefferson Tenório Rocha, Frederico Medeiros Buhatem, Machado Orsini de, S. Pinto
Low grade myofibroblastic sarcoma is an atypical myofibroblastic malignant neoplasm that rarely affects the oral cavity and presents a challenging histological diagnosis. Here we report the case of a 38-year-old woman who had a nodular and symptomatic lesion on the lateral border of the tongue. After the biopsy, the histopathological analysis revealed a spindle cell lesion with fascicular and storiform pattern. We performed immunohistochemical analysis that showed intense labeling for vimentin, smooth muscle actin and moderate labeling for calponin and S-100. We emphasize the rarity of low grade myofibroblastic sarcoma such as a nodular lesion on the tongue and the need for accurate diagnosis.
{"title":"Nodular lesion in the tongue: A rare case of low grade myofibroblastic sarcoma","authors":"Jefferson Tenório Rocha, Frederico Medeiros Buhatem, Machado Orsini de, S. Pinto","doi":"10.2298/aoo190827009t","DOIUrl":"https://doi.org/10.2298/aoo190827009t","url":null,"abstract":"Low grade myofibroblastic sarcoma is an atypical myofibroblastic malignant neoplasm that rarely affects the oral cavity and presents a challenging histological diagnosis. Here we report the case of a 38-year-old woman who had a nodular and symptomatic lesion on the lateral border of the tongue. After the biopsy, the histopathological analysis revealed a spindle cell lesion with fascicular and storiform pattern. We performed immunohistochemical analysis that showed intense labeling for vimentin, smooth muscle actin and moderate labeling for calponin and S-100. We emphasize the rarity of low grade myofibroblastic sarcoma such as a nodular lesion on the tongue and the need for accurate diagnosis.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68402802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. M. Knickerbocker, D. Timmons, Y. Tjendra, S. Garzon, J. Carugno
Pseudoangiomatous stromal hyperplasia is a benign proliferative lesion of the breast tissue that typically affects women in the reproductive age. Pseudoangiomatous stromal hyperplasia usually presents as a localized, painless, firm mass or as a diffuse thickened area of the breast. Rarely, it can arise along the embryonic milk line, up to the anogenital region, where it simulates angiosarcomas. Awareness of this uncommon condition is important in order to avoid unnecessary aggressive excisional surgical procedures. For this purpose, we present a case of nodular pseudoangiomatous stromal hyperplasia arising in the vulva in a patient with recurrent pseudoangiomatous stromal hyperplasia of the breast.
{"title":"Association of a large vulvar tumor in a in a young premenopausal woman with recurrent pseudoangiomatous stromal hyperplasia of the breasts","authors":"A. M. Knickerbocker, D. Timmons, Y. Tjendra, S. Garzon, J. Carugno","doi":"10.2298/aoo190603008k","DOIUrl":"https://doi.org/10.2298/aoo190603008k","url":null,"abstract":"Pseudoangiomatous stromal hyperplasia is a benign proliferative lesion of the breast tissue that typically affects women in the reproductive age. Pseudoangiomatous stromal hyperplasia usually presents as a localized, painless, firm mass or as a diffuse thickened area of the breast. Rarely, it can arise along the embryonic milk line, up to the anogenital region, where it simulates angiosarcomas. Awareness of this uncommon condition is important in order to avoid unnecessary aggressive excisional surgical procedures. For this purpose, we present a case of nodular pseudoangiomatous stromal hyperplasia arising in the vulva in a patient with recurrent pseudoangiomatous stromal hyperplasia of the breast.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68402707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Djurić, D. Lukić, Z. Radovanovic, Aleksandar Ðermanovic, M. Ranisavljevic, B. Gutic
Introduction: The ?gold standard? for patients with locally advanced rectal cancer is neoadjuvant chemoradiotherapy followed by surgery. Aim: Evaluation of local recurrence after surgery for locally advanced rectal cancer. Methods and patients: Retrospective study included 189 patients, who were operated at Oncology Institute of Vojvodina from January 1st 2012 until December 31st 2017. Patients were divided into two groups. In the first group 73 patients who received chemoradiotherapy were included, while 116 patients without neoadjuvant treatment were in the second group. All patients were diagnosed with locally advanced rectal cancer. The existence of operable metastases in the liver and/or lungs did not exclude patients from the study. Patients who had undergone resection of the rectum by Miles, Hartmann or local tumor excision were excluded from the study. Results: The median follow-up period was 48 months (range 13-84). In total, 23 (12.2%) patients developed local recurrence. In the chemoradiotherapy group, 15.1% (11 of 73 patients) had a local recurrence, as compared with 10.3% (12 of 116 patients) in the group without neoadjuvant treatment. In both groups, there were no correlation between rate of local recurrence with other clinical and pathological parameters such as gender, tumor location, T and N stage, histological differentiation, or lymphovascular and perineural invasion (p>0.05). We confirmed significant association between circumferential resection margin with local recurrence in patients who were treated by preoperative chemoradiation (p=0.014). Conclusion: This study has not shown reduced risk of local recurrence after neoadjuvant therapy most likely due to small number of patients. Despite our results, neoadjuvant treatment followed by surgery remains the best treatment protocol for patients with locally advanced rectal cancer.
{"title":"Local recurrence after surgery of locally advanced rectal cancer treated with or without preoperative chemoradiotherapy","authors":"M. Djurić, D. Lukić, Z. Radovanovic, Aleksandar Ðermanovic, M. Ranisavljevic, B. Gutic","doi":"10.2298/aoo190717010d","DOIUrl":"https://doi.org/10.2298/aoo190717010d","url":null,"abstract":"Introduction: The ?gold standard? for patients with locally advanced rectal cancer is neoadjuvant chemoradiotherapy followed by surgery. Aim: Evaluation of local recurrence after surgery for locally advanced rectal cancer. Methods and patients: Retrospective study included 189 patients, who were operated at Oncology Institute of Vojvodina from January 1st 2012 until December 31st 2017. Patients were divided into two groups. In the first group 73 patients who received chemoradiotherapy were included, while 116 patients without neoadjuvant treatment were in the second group. All patients were diagnosed with locally advanced rectal cancer. The existence of operable metastases in the liver and/or lungs did not exclude patients from the study. Patients who had undergone resection of the rectum by Miles, Hartmann or local tumor excision were excluded from the study. Results: The median follow-up period was 48 months (range 13-84). In total, 23 (12.2%) patients developed local recurrence. In the chemoradiotherapy group, 15.1% (11 of 73 patients) had a local recurrence, as compared with 10.3% (12 of 116 patients) in the group without neoadjuvant treatment. In both groups, there were no correlation between rate of local recurrence with other clinical and pathological parameters such as gender, tumor location, T and N stage, histological differentiation, or lymphovascular and perineural invasion (p>0.05). We confirmed significant association between circumferential resection margin with local recurrence in patients who were treated by preoperative chemoradiation (p=0.014). Conclusion: This study has not shown reduced risk of local recurrence after neoadjuvant therapy most likely due to small number of patients. Despite our results, neoadjuvant treatment followed by surgery remains the best treatment protocol for patients with locally advanced rectal cancer.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68402793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Sayad, Seyyed Ahmadi Amir, Reza Nekouian, M. Panahi, K. Anbari
Background: Present study aimed to investigate immunohistochemical parameters in post-surgical cases of invasive breast cancer. Methods: In this single center cross-sectional study we investigated ethnicity, familial history, type of cancer, stage of cancer, lymph node positivity, bilateral involvement, metastasis and immunohistochemical parameters (estrogen and progesterone receptor, human epidermal growth factor receptor 2, as well as frequency of triple positive and triple negative patients merely based on immunohistochemical parameters). Results: Frequency of positive familial history was 27.42% (16.31-38.52%). Lymph node involvement was detected in 55.93% (43.26-68.60%) of the cases. Frequency of positive HER2 was 38.60% (25.96-51.23%). There were 17.54% (7.67-27.42%) of triple positive and 7.02% (0.39-13.65%) of triple negative cases. The most common stage at the time of diagnosis was stage 3 with 43.33% (30.79-55.87%) frequency. In Lur/Lak population higher frequency of positive HER2 cases was detected whereas in Mazani population frequency of positive HER2 cases was low (p=0.0291). Conclusions: These results could contribute to understanding of breast cancer patterns among different ethnicities. In order to draw clear conclusion future investigations have to be done in several health centers, for longer time periods and with larger number of patients.
{"title":"Epidemiological and pathological characteristics of post-surgical cases of invasive breast cancer among ethnicities of Iran in 2018: A single center cross-sectional study","authors":"S. Sayad, Seyyed Ahmadi Amir, Reza Nekouian, M. Panahi, K. Anbari","doi":"10.2298/aoo190626007s","DOIUrl":"https://doi.org/10.2298/aoo190626007s","url":null,"abstract":"Background: Present study aimed to investigate immunohistochemical parameters in post-surgical cases of invasive breast cancer. Methods: In this single center cross-sectional study we investigated ethnicity, familial history, type of cancer, stage of cancer, lymph node positivity, bilateral involvement, metastasis and immunohistochemical parameters (estrogen and progesterone receptor, human epidermal growth factor receptor 2, as well as frequency of triple positive and triple negative patients merely based on immunohistochemical parameters). Results: Frequency of positive familial history was 27.42% (16.31-38.52%). Lymph node involvement was detected in 55.93% (43.26-68.60%) of the cases. Frequency of positive HER2 was 38.60% (25.96-51.23%). There were 17.54% (7.67-27.42%) of triple positive and 7.02% (0.39-13.65%) of triple negative cases. The most common stage at the time of diagnosis was stage 3 with 43.33% (30.79-55.87%) frequency. In Lur/Lak population higher frequency of positive HER2 cases was detected whereas in Mazani population frequency of positive HER2 cases was low (p=0.0291). Conclusions: These results could contribute to understanding of breast cancer patterns among different ethnicities. In order to draw clear conclusion future investigations have to be done in several health centers, for longer time periods and with larger number of patients.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68402746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Makazlieva, O. Vaskova, Aleksandra Nikolovska, V. Stefanovska
Background: The most common thyroid tumors originate from the epithelial follicular cells. Etiology involved in the development of thyroid carcinoma is multifactorial, including external influences and genetic predisposition. Aim: The objective of our study was to analyze the distribution of the histopathological types of thyroid carcinoma during 1999- 2015 year period, to evaluate papillary and follicular thyroid carcinoma ratio and to compare thyroid carcinoma types with the data from prior epidemiological study referring to the period from 1966 -1988. Methods: A retrospective analysis was performed. The trend for thyroid carcinoma cases was evaluated in the time period of 50 years. Percentages of different histopathological types of thyroid carcinoma were presented and papillary and follicular thyroid carcinoma ratio was calculated for the two evaluated periods. Results: A total number of 422 thyroid carcinoma patients were diagnosed in the 1999-2015 year period vs. 323 patients in the period from 1966-1988. Analysis revealed no statistically significant difference in histopathological types of thyroid carcinoma during 1999-2015 year period, but statistically significant difference was detected between the two analyzed periods with a significant increase of papillary and follicular thyroid carcinoma ratio (from 3.1 to 7.3), and a significant reduction of anaplastic thyroid carcinomas cases in the more recent evaluated period (1999-2015). Conclusion: The analysis of the fifty-year-period in population of North Macedonia showed an increase in number of thyroid carcinoma cases, especially papillary and reduction of follicular thyroid carcinoma and anaplastic thyroid carcinomas cases. Further, genetic profiling studies could be useful in evaluating possible mechanisms behind this shift in histopathology of the thyroid carcinomas.
{"title":"Distribution of histopathological types of thyroid tumors in 1999-2015 compared to 1966-1988 year period","authors":"T. Makazlieva, O. Vaskova, Aleksandra Nikolovska, V. Stefanovska","doi":"10.2298/aoo190402005m","DOIUrl":"https://doi.org/10.2298/aoo190402005m","url":null,"abstract":"Background: The most common thyroid tumors originate from the epithelial follicular cells. Etiology involved in the development of thyroid carcinoma is multifactorial, including external influences and genetic predisposition. Aim: The objective of our study was to analyze the distribution of the histopathological types of thyroid carcinoma during 1999- 2015 year period, to evaluate papillary and follicular thyroid carcinoma ratio and to compare thyroid carcinoma types with the data from prior epidemiological study referring to the period from 1966 -1988. Methods: A retrospective analysis was performed. The trend for thyroid carcinoma cases was evaluated in the time period of 50 years. Percentages of different histopathological types of thyroid carcinoma were presented and papillary and follicular thyroid carcinoma ratio was calculated for the two evaluated periods. Results: A total number of 422 thyroid carcinoma patients were diagnosed in the 1999-2015 year period vs. 323 patients in the period from 1966-1988. Analysis revealed no statistically significant difference in histopathological types of thyroid carcinoma during 1999-2015 year period, but statistically significant difference was detected between the two analyzed periods with a significant increase of papillary and follicular thyroid carcinoma ratio (from 3.1 to 7.3), and a significant reduction of anaplastic thyroid carcinomas cases in the more recent evaluated period (1999-2015). Conclusion: The analysis of the fifty-year-period in population of North Macedonia showed an increase in number of thyroid carcinoma cases, especially papillary and reduction of follicular thyroid carcinoma and anaplastic thyroid carcinomas cases. Further, genetic profiling studies could be useful in evaluating possible mechanisms behind this shift in histopathology of the thyroid carcinomas.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68402625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Immune checkpoint inhibitor therapy has become increasingly more used as a treatment modality for solid organ tumors. Nivolumab, anti-PD-1 and Ipilimumab, anti-CTLA-4 monoclonal antibodies are checkpoint inhibitors with well described immune related toxicities. Immune specific neurotoxicity is rare and not well elucidated in literature. We present a case of severe autoimmune encephalitis in a patient with metastatic renal cell carcinoma treated with both Nivolumab and Ipilimumab. A 53-year-old man with metastatic renal cell carcinoma presented due to visual and auditory hallucinations of sudden onset, confusion and weakness. Initial imaging and diagnostic workup did not demonstrate a clear source. However, a neurological etiology was suspected. It was concluded that the patient had autoimmune encephalitis induced by dual check point inhibitor therapy. This was further strengthened by his rapid response to systemic corticosteroid therapy. We present a summary of this case and its management and a review of literature on dual checkpoint inhibitor induced neurological adverse effects.
{"title":"Dual checkpoint inhibitor induced autoimmune encephalitis","authors":"Natalie Elkayam, Shaurya Sharma","doi":"10.2298/AOO181230003E","DOIUrl":"https://doi.org/10.2298/AOO181230003E","url":null,"abstract":"Immune checkpoint inhibitor therapy has become increasingly more used as a treatment modality for solid organ tumors. Nivolumab, anti-PD-1 and Ipilimumab, anti-CTLA-4 monoclonal antibodies are checkpoint inhibitors with well described immune related toxicities. Immune specific neurotoxicity is rare and not well elucidated in literature. We present a case of severe autoimmune encephalitis in a patient with metastatic renal cell carcinoma treated with both Nivolumab and Ipilimumab. A 53-year-old man with metastatic renal cell carcinoma presented due to visual and auditory hallucinations of sudden onset, confusion and weakness. Initial imaging and diagnostic workup did not demonstrate a clear source. However, a neurological etiology was suspected. It was concluded that the patient had autoimmune encephalitis induced by dual check point inhibitor therapy. This was further strengthened by his rapid response to systemic corticosteroid therapy. We present a summary of this case and its management and a review of literature on dual checkpoint inhibitor induced neurological adverse effects.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68403015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：